Supplementary Table S1. Additional entry criteria not described within the text

Description of inclusion criteria
• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of <1% per year, during the treatment period and for at least 3 months after the final follow-up visit
• For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm
Description of exclusion criteria
• Clinical evidence of active infection
• Any condition that is likely to result in death in the 12 months after the start of screening
• Lung transplantation anticipated or any planned significant surgical intervention
• Known hypersensitivity to the active substance or any excipient of either pirfenidone or nintedanib
• Hepatic impairment and/or severe renal impairment
• History of GI tract perforation, unstable or deteriorating cardiac or pulmonary disease (other than IPF), long QT syndrome, alcohol or substance abuse, use of any tobacco product, etc
• Bleeding risk
• Pregnancy or lactation

GI, gastrointestinal; IPF, idiopathic pulmonary fibrosis; QT interval, time between Q and T waves.